Monospecific monoclonal antibodies against human transcription factors

抗人类转录因子的单特异性单克隆抗体

基本信息

批准号：
8916172
负责人：
Seth Blackshaw
金额：
$ 287.63万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-26 至 2016-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8916172
关键词：
Affinity Antibodies Antibody Affinity Antigens Area Award Biochemical Biological Assay Cell Extracts Cell Line Cells ChIP-on-chip ChIP-seq Chromatin Cloud Computing Code Collection Cultured Cells Custom DNA Data Databases Development Diagnostic Ensure Evaluation Expression Library Funding Future Generic Drugs Goals Health Histones Human Human Genome Hybridomas Image Incidence Injection of therapeutic agent Measurement Medicine Methods Monoclonal Antibodies Policies Process Production Protein Microchips Proteins Proteome Reagent Recombinant Proteins Recombinants Request for Applications Research Resolution Scientist Specificity Speed System Testing Tetanus Helper Peptide Therapeutic United States National Institutes of Health Validation Yeasts base biophysical techniques cost cost effective expression vector flexibility human tissue improved knock-down novel promoter protein expression scale up small hairpin RNA tissue culture tool transcription factor

项目摘要

(same as original) This is a proposal to create a production center capable of implementing a pipeline that includes acquisition and evaluation of human transcription factor immunogens, production and selection of monospecific Monoclonal antibodies (mMAbs), and biochemical characterization and validation of these protein capture (affinity) reagents. We emphasize the advantages of high throughput and scalability to be achieved within our production effort, and propose the development of process improvements, thereby improving cost and quality over the duration of the award. We will maintain a degree of scientific flexibility to develop approaches to producing affinity reagents to less tractable transcription factor protein targets as they are identified in the course of production. Finally we propose a viable distribution plan consistent with NIH policies, utilizing the existing Developmental Hybridoma Monoclonal Bank, which ensures broad availability and wide accessibility for future use of the reagents with minimal constraints, consistent with achieving the goals of this funding initiative.

（与原始相同）这是创建一个能够实施包括的管道的生产中心的建议人类转录因子免疫原子的获取和评估，生产和选择单特异性单克隆抗体（MMAB）以及生化表征和验证这些蛋白质捕获（亲和力）试剂。我们强调在我们的内部实现高吞吐量和可扩展性的优势生产工作，并提出改进过程的发展，从而提高成本和质量在整个奖项期间。我们将保持一定程度的科学灵活性开发产生亲和力试剂的方法在生产过程中确定的目标。最后，我们提出了一个与NIH政策一致的可行分配计划，利用现有发育性杂交瘤单克隆银行，可确保广泛的可用性和广泛可访问性，用于将来使用具有最小限制的试剂，这与实现这项资金计划的目标。